Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.13 -7.9%	$10.23	$4.88 ▼ $19.58	$241.52M	N/A	29,005 shs	51,988 shs
ACRV Acrivon Therapeutics	$1.18 -4.8%	$1.36	$1.05 ▼ $10.16	$36.99M	1.56	254,280 shs	251,221 shs
INBX Inhibrx Biosciences	$14.93 -1.8%	$12.79	$10.80 ▼ $17.79	$216.19M	N/A	100,859 shs	132,762 shs
PROK ProKidney	$0.66 -5.2%	$0.81	$0.46 ▼ $2.59	$193.21M	1.36	635,104 shs	1.80 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	+3.63%	+6.00%	+20.45%	+1,112,999,900.00%
ACRV Acrivon Therapeutics	0.00%	-1.67%	+0.85%	-78.97%	-82.15%
INBX Inhibrx Biosciences	0.00%	+2.47%	+16.10%	+1.43%	-1.39%
PROK ProKidney	0.00%	-21.26%	-7.11%	-35.28%	-73.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACRV Acrivon Therapeutics	3.6417 of 5 stars	4.5	5.0	0.0	0.0	0.6	2.5	0.6
INBX Inhibrx Biosciences	2.0622 of 5 stars	0.0	3.0	0.0	4.6	0.0	1.7	1.3
PROK ProKidney	1.6781 of 5 stars	3.2	0.0	0.0	0.0	0.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	180.77% Upside
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,401.21% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
PROK ProKidney	2.33	Hold	$4.50	581.71% Upside

Current Analyst Ratings Breakdown

Latest ACRV, INBX, PROK, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/1/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
3/27/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
INBX Inhibrx Biosciences	$200K	1,080.93	$114.85 per share	0.13	$9.23 per share	1.62
PROK ProKidney	$80K	2,415.14	N/A	N/A	($3.41) per share	-0.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.13	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest ACRV, INBX, PROK, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
ACRV Acrivon Therapeutics	N/A	11.17	11.17
INBX Inhibrx Biosciences	1.04	5.12	5.12
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ACRV Acrivon Therapeutics	71.62%
INBX Inhibrx Biosciences	82.46%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
ACRV Acrivon Therapeutics	8.50%
INBX Inhibrx Biosciences	N/A
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
ACRV Acrivon Therapeutics	58	31.35 million	28.69 million	Not Optionable
INBX Inhibrx Biosciences	166	14.48 million	N/A	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

ACRV, INBX, PROK, and AARD Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Has $740,000 Stake in ProKidney Corp. (NASDAQ:PROK)

June 8, 2025 | marketbeat.com

ProKidney quarterly loss grows as it nears two key milestones

May 15, 2025 | journalnow.com

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

May 12, 2025 | globenewswire.com

Another Big Office Landlord Tests Sales Climate

May 12, 2025 | bankerandtradesman.com

PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More

May 9, 2025 | nasdaq.com

Why ProKidney Corp.’s (PROK) Stock Is Down 6.09%

April 28, 2025 | aaii.com

Insider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of Stock

April 25, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 7.90%

April 17, 2025 | aaii.com

ProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in Stock

April 17, 2025 | insidertrades.com

Greensboro’s Once Great Win Is Now A ProKidney Failure

April 16, 2025 | rhinotimes.com

Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

April 15, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 9.90%

April 10, 2025 | aaii.com

Why ProKidney Corp.’s (PROK) Stock Is Down 14.87%

April 8, 2025 | aaii.com

ProKidney Corp.

March 30, 2025 | wsj.com

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

March 27, 2025 | finance.yahoo.com

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

March 21, 2025 | zacks.com

ProKidney reports larger loss in 2024 as production resumes

March 18, 2025 | journalnow.com

ProKidney reports FY24 EPS (62c), consensus (59c)

March 17, 2025 | markets.businessinsider.com

ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease

March 17, 2025 | quiverquant.com

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

March 17, 2025 | globenewswire.com

Why ProKidney Corp.’s (PROK) Stock Is Down 10.96%

February 26, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, INBX, PROK, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.13 -0.95 (-7.86%)

As of 06/20/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Acrivon Therapeutics NASDAQ:ACRV

$1.18 -0.06 (-4.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.04 (+3.39%)

As of 06/20/2025 07:56 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Inhibrx Biosciences NASDAQ:INBX

$14.93 -0.28 (-1.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.97 +0.04 (+0.27%)

As of 06/20/2025 04:04 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

ProKidney NASDAQ:PROK

$0.66 -0.04 (-5.20%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.73 +0.07 (+10.59%)

As of 06/20/2025 07:58 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time